Training | 2016.06.21
Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
Developing predictive drug sensitivity assays using cancer patient cells is one of the promises of personalized medicine. Next generation platforms must integrate immune profiling in physiologically relevant ex-vivo microenvironments to ensure clinical translation of laboratory results.
(PRWeb June 20, 2016)
Read the full story at http://www.prweb.com/releases/2016/06/prweb13493909.htm
For more information, please visit
http://www.prweb.com/releases/2016/06/prweb13493909.htm
